to Cornell while Angiocrine retains full commercial rights. Other highlights: • Signed a 3-year Corporate Agreement with TerumoBCT, a division of Terumo Corporation (publicly-traded, global medical device company with a $15B market cap, headquartered in Tokyo) • Achieved positive pre-clinical proof-of-concept